IP Library Granted Patent US 9,265,798
Granted Patent B2
US 9,265,798 · App. 14/711,429 · Granted Feb 23, 2016

Method and system for treatment of cardiovascular disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,265,798
App. No.
14/711,429
Granted
Feb 23, 2016
Kind
B2
Abstract

Methods for treating a cardiovascular disorder comprising administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance.

Claims (7)

1. A method of treating a cardiovascular disorder in a subject, comprising:

providing an extracellular matrix (ECM) composition comprising acellular bioremodelable mesothelial tissue, said mesothelial tissue comprising endogenous proteoglycans, transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF) that collectively induce myofibroblast and stem cell migration, and differentiation of said stem cells into cardiomyocytes when administered to damaged cardiovascular tissue;

providing a mechanical circulatory support (MSC) device that is configured to support ventricular function of a mammalian heart when connected thereto;

connecting said MSC device to said subject's circulatory system;

administering said ECM composition proximate damaged cardiovascular tissue of said subject's heart, wherein said ECM composition induces neovascularization and bioremodeling of said subject's damaged cardiovascular tissue; and

providing support of ventricular function of said subject's heart with said MSC device.

2. The method of claim 1 , wherein said ECM composition is administered directly to said subject's damaged cardiovascular tissue.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: CORMATRIX CARDIOVASCULAR, INC.
To: CORVIVO CARDIOVASCULAR, INC.
Reel/Frame 070481/0747 →